Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+-K+-ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes

Naka, Keigo; Sasaki, Hideyuki; Kishi, Yutaka; Furuta, Machi; Sanke, Tokio; Nanjo, Kishio; Mukoyama, Masakuni

doi:10.1016/0168-8227(95)01184-6

Cited by 21 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although cilostazol is primarily used in peripheral vascular diseases, this compound has recently gained much greater favor in the prevention and treatment of diabetic complications, including vasculopathy (Gao et al, 2006;Yamasaki et al, 2006), neuropathy (Naka et al, 1995;Yamamoto et al, 2000), and retinopathy (Hotta et al, 1997). We found in the current study that cilostazol could also suppress the characteristic changes in early DN, such as glomerular hyperplasia, inflammatory cells infiltration and increased relative kidney weight (g kg − 1 body weight), ultimately hampering the progression of DN.…”

Section: Discussionmentioning

confidence: 98%

Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats

et al. 2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats

et al. 2008

View full text Add to dashboard Cite

“…Another explanation is the impairment of Na + /K + -ATPase, a cation membrane transporter. There are reports of altered Na + /K + -ATPase function in myocardial cells of noninsulin-dependent and insulin-dependent DM [46], in cerebral cortex [47] and in peripheral nerves [48] of STZ diabetes-induced adult rats. We found approximately 4-5 mV of depolarization in hyperglycemic animals, and this value is compatible with Na + /K + -ATPase contribution to neuron resting membrane potential [40].…”

Section: Discussionmentioning

confidence: 99%

n5-STZ Diabetic Model Develops Alterations in Sciatic Nerve and Dorsal Root Ganglia Neurons of Wistar Rats

et al. 2013

View full text Add to dashboard Cite

One experimental model of diabetes mellitus (DM) similar to type II DM, called n5-STZ, is obtained by a single injection (via i.p.) of streptozotocin (STZ) in the 5th day of life of newborn rats. The present investigation aimed to characterize alterations in excitability of rat peripheral neurons in n5-STZ model. n5-STZ DM was induced, and electrophysiological evaluation was done at 12th week of rat life. Rats developed glucose intolerance, sensory alteration, and hyperglycemia or near-normoglycemia (21.2 ± 1.6 and 7.4 ± 0.4 mmol/L). In near-normoglycemia group the significant electrophysiological alteration observed was decreased in amplitude of 2nd wave (2nd component, conduction velocity: 48.8 m/s) of compound action potential (CAP) of sciatic nerve. For hyperglycemic rats, decreased excitability, amplitude, and conduction velocity of 2nd CAP component of sciatic nerve were found; a depolarization of resting potential (4-5 mV) and reduction in maximum ascendant and descendant inclinations of action potential were found in DRG neurons but no alteration on Na+ current (INa+). Thus, n5-STZ rats develop alterations in excitability which were related to glycemic levels but were not likely attributable to changes on INa+. Our data confirm that n5-STZ model is a useful model to study type II DM.

show abstract

“…O cilostazol melhorou a atividade da bomba de sódio e potássio corrigindo o fluxo sangüíneo e a hipóxia neural, através de ações na microvascularização endoneural, por agir no metabolismo das prostaglandinas e do óxido nítrico (57). Tem ação na morfologia da fibra mielínica através da diminuição da atrofia axonal, por facilitar o aporte de proteínas cito-esqueléticas devido ao bloqueio da inflamação neurogênica e chegada de macrófagos nesses sítios.…”

Section: Ações Do Cilostazol Na Prevenção E No Tratamento Das Complicunclassified

Potencial terapêutico para a prevenção e tratamento da nefropatia e neuropatia diabéticas: evidências do uso do cilostazol

Rosa

Baroni

Portal

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO cilostazol é um inibidor seletivo da fosfodiesterase tipo III com ação vasodilatadora, antiagregante plaquetária e antitrombótica. É considerada a droga de primeira escolha na claudicação intermitente devido à doença arterial obstrutiva periférica. Vários estudos demonstraram melhora significativa na distância percorrida na caminhada sem dor e na qualidade de vida, sem aumentar o risco de sangramento. Essas ações também foram verificadas em pacientes diabéticos, pois o cilostazol não afeta o metabolismo da glicose. Estudos, principalmente experimentais, têm mostrado resultados satisfatórios na melhora do fluxo sangüíneo neural, na atividade da bomba de sódio e potássio, na resistência à insulina e na microalbuminúria. Neste artigo, apresentamos uma revisão do uso do cilostazol na prevenção e no tratamento das complicações do diabetes mellitus, como nefropatia e neuropatia. Ressalta-se a necessidade do controle adequado dos níveis glicêmicos, da hipertensão arterial sistêmica e do tabagismo. Um maior número de estudos clínicos é necessário para melhor compreensão desses efeitos benéficos. Cilostazol, a selective phosphodiesterase type III inhibitor, has vasodilatory, antiplatelet, and antithrombotic actions, as well as being the first-choice drug for the intermittent claudication due to peripheral vascular disease. Main researches have demonstrated significant improvement for this situation, including patients with diabetes mellitus, concerning pain-free walking distance and quality-of-life, not rising the bleeding event risk. It does not affect the glucose metabolism even in patients suffering from diabetes. This paper aims to present a review on the discoveries of various studies, most of them experimental, on the prevention and treatment of diabetes mellitus complications, such as nephropathy and neuropathy, through the use of cilostazol, which demonstrated satisfactory results on the improvement in neural blood flow, on sodium-potassium ATPase activity, on insulin resistance, and microalbuminuria. However, strict controlling of glucose plasma levels, hypertension, and smoking habits, as well as more extended investigations on the matter are required to the better comprehension. (Arq Bras Endocrinol Metab 2007;51/9:1528-1532)

show abstract

Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+-K+-ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes

Cited by 21 publications

References 24 publications

Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats

Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats

n5-STZ Diabetic Model Develops Alterations in Sciatic Nerve and Dorsal Root Ganglia Neurons of Wistar Rats

Potencial terapêutico para a prevenção e tratamento da nefropatia e neuropatia diabéticas: evidências do uso do cilostazol

Contact Info

Product

Resources

About